These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29554182)

  • 1. Considerations for Cost-effectiveness Analysis of Curative Pediatric Therapies.
    Whittington MD; McQueen RB; Campbell JD
    JAMA Pediatr; 2018 May; 172(5):409-410. PubMed ID: 29554182
    [No Abstract]   [Full Text] [Related]  

  • 2. Rollout of high-priced cell and gene therapies forces payer rethink.
    Senior M
    Nat Biotechnol; 2018 Apr; 36(4):291-292. PubMed ID: 29621215
    [No Abstract]   [Full Text] [Related]  

  • 3. The high price of progress.
    Nat Rev Clin Oncol; 2017 Feb; 14(3):129. PubMed ID: 28218258
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing patient value and payer cost in hematologic malignancies: can it be done?
    Allen PB; Flowers CR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):123-126. PubMed ID: 29486601
    [No Abstract]   [Full Text] [Related]  

  • 5. Approvals in 2016: questioning the clinical benefit of anticancer therapies.
    Booth CM; Del Paggio JC
    Nat Rev Clin Oncol; 2017 Feb; 14(3):135-136. PubMed ID: 28218259
    [No Abstract]   [Full Text] [Related]  

  • 6. Kymriah: A Sign of More Difficult Decisions To Come.
    Silverman E
    Manag Care; 2018 May; 27(5):17. PubMed ID: 29763402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approvals in 2016: cost-benefit challenges of new anticancer agents.
    Savage P
    Nat Rev Clin Oncol; 2017 Feb; 14(3):133-134. PubMed ID: 28218257
    [No Abstract]   [Full Text] [Related]  

  • 8. CAR T-cell therapy: perceived need versus actual evidence.
    The Lancet Oncology
    Lancet Oncol; 2018 Oct; 19(10):1259. PubMed ID: 30303110
    [No Abstract]   [Full Text] [Related]  

  • 9. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
    [No Abstract]   [Full Text] [Related]  

  • 11. Being NICE is not the problem!
    Jonsson B
    Eur J Cancer; 2009 May; 45(7):1100-1102. PubMed ID: 19268570
    [No Abstract]   [Full Text] [Related]  

  • 12. NICE, the NHS, and Cancer Drugs.
    Dillon A; Landells LJ
    JAMA; 2018 Feb; 319(8):767-768. PubMed ID: 29387883
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current issues concerning drug development for pediatric hematologic malignancies].
    Sekimizu M
    Rinsho Ketsueki; 2016 Jun; 57(6):693-700. PubMed ID: 27384847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Must Sky-High Prices 'Come on Down' Before the Price Is Right?
    Kirkner RM
    Manag Care; 2018 Jul; 27(7):16-19. PubMed ID: 29989894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hematology: experiences with common national reports on new anti-cancer drugs].
    Kristensen JS; Bukh A
    Ugeskr Laeger; 2009 Mar; 171(13):1089. PubMed ID: 19321084
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review.
    Lien K; Cheung MC; Chan KK
    J Oncol Pract; 2016 Apr; 12(4):e369-79. PubMed ID: 26330534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer drugs: high price, uncertain value.
    Cohen D
    BMJ; 2017 Oct; 359():j4543. PubMed ID: 28978508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
    Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
    J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab emtansine and cost-based decision making.
    The Lancet
    Lancet; 2017 Jan; 389(10064):2. PubMed ID: 28091366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.